Prognostic value of serum interleukin-6 in diffuse large-cell lymphona

Annals of Internal Medicine

Volumn 127, Issue 3, 1997, Pages 186-194

  Preti, H Alejandro ^b   Cabanillas, Fernando ^a   Talpaz, Moshe ^a   Tucker, Susan L ^a   Seymour, John F ^c   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b 1425 Capital Federal ^*  (Argentina)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION FUNCTION; DIAGNOSTIC VALUE; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0030861218     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-3-199708010-00002     Document Type: Article

References (40)

1. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol. 1990;8:253-7.
2. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86:1243-54.
3. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265:621-36.
4. Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H. Interleukin-6 is a prognostic factor in multiple myeloma [Letter]. Blood. 1991;77:2794-5.
5. Nachbaur DM, Herald M, Maneschg A, Huber H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol. 1991;62:54-8.
6. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863-72.
7. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castelman's disease. Blood. 1989;74:1360-7.
8. Woodroofe C, Muller W, Ruther U. Long-term consequences of interleukin-6 overexpression in transgenic mice. DNA Cell Biol. 1992;11:587-92.
9. Scala G, Quinto I, Ruocco MR, Arcucci A, Mallardo M, Caretto P, et al. Expression of an exogenous interleukin 6 in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. J Exp Med. 1990;172: 61-8.
10. Pluda JM, Venzon DJ, Tosato G, Lietzau J, Wyvill K, Nelson DL, et al. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol. 1993;11:1099-107.
11. Tosato G, Jones K, Breinig MK, McWilliams HP, McKnight JL. Interleukin-6 production in posttranplant lymphoproliferative disease. J Clin Invest. 1993;91:2806-14.
12. Freeman GJ, Freedman AS, Rabinowe SN, Segil JM, Horowitz J, Rosen K, et al. Interleukin 6 gene expression in normal and neoplastic B cells. J Clin Invest. 1989;83:1512-8.
13. Chang H, Jamal N, Wang XH, Minden MD, Messner HA. Constitutive production of the interleukins IL-5 and IL-6 by the lymphoma cell line OCI-Ly 17 derived from a patients with malignant lympoma and hypereosinophilia. Leuk Lymphoma. 1992;8:97-107.
14. Yee C, Blondi A, Wang XH, Iscove NN, de Sousa J, Aarden LA, et al. A possible autocrine rale for interleukin-6 in two lymphoma cell lines. Blood. 1989;74:798-804.
15. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al. Serum level of interleukin 6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res. 1992;52;3317-22.
16. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 1991;164:1038-43.
17. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology. 1995;45:542-9.
18. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M. Serum interleukin 6 levels are elevated in lymphoma paitents and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res. 1993;53:2118-22.
19. Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol. 1995;13:575-82.
20. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982;49:2112-35.
21. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630-6.
22. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. M Engl J Med. 1993; 329:987-94.
23. Cabanillas F, Rodriguez MA, Swan F Jr. Recent trends in the management of lymphomas at M.D. Anderson Cancer Center. Semin Oncol. 1990;17:28-34.
24. Velasquez WS, Jagannath S, Tucker SL, Fuller LM, North LB, Redman JR, et al. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood. 1989;74:551-7.
25. Swan F Jr, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, McLaughlin P, et al. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol. 1989;7:1518-27.
26. Altman DG. Practical Statistics for Medical Research. New York: Chapman & Hall; 1991.
27. 2 from contingency tables and the calculation of P. Journal of the Royal Statistical Society. 1922;85:87-94.
28. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bulletin. 1945;1:80-83.
29. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. Journal of the American Statistical Association. 1958;53:457-81.
30. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-70.
31. Cox DR. Regression models and life tables. Journal of the Statistical Society of Britain. 1972;34:187-202.
32. Gause A, Scholz R, Klein S, Jung W, Diehl V, Tesch H, et al. Increased levels of circulating interleukin-6 in patients with Hodgkin's disease. Hematol Oncol. 1991;9:307-13.
33. Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R. Clinical correlates of elevated serum levels of interleukin-6 in patients with untreated Hodgkin's disease. Am J Med. 1997;102:21-8.
34. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood. 1994;83:1165-73.
35. Grogan TM, Lippman SM, Spier CM, Slymen DJ, Rybski JA, Rangel CS, et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood. 1988;71:1157-61.
36. Horst E, Meijer CJ, Radaszkiewicz T, Ossekoppele GJ, Van Krieken JH, Pals ST. Adhesion molecules in the prognosis of diffuse large cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia. 1990;4:595-9.
37. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332:83-5.
38. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993;83:3712-6.
39. Emilie D, Wijdenes J, Gisselbrecht C, Jarrousse B, Billaud E, Blay JY, et al. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and B clinical symptoms. Blood. 1994;84:2472-9.
40. Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood. 1995;86:3123-31.